A letter from the FDA citing deficiencies in its treatment for moderate to severe dysparaeunia due to vulvar vaginal atrophy had a negative impact on TherapeuticsMD stock, but it was not a death sentence…
Cytori Therapeutics saw its shares explode after it was reported that the firm received approval from the FDA for its treatment of thermal burn injuries.
OncoMed Pharmaceuticals saw its shares crumble after the company announced that Bayer Pharma is terminating its option agreement with the company as well as a missed mid-stage trial.
A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology stocks.
Biohaven Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Catalyst Biosciences watched its shares fall on Friday following the announcement of a secondary offering.
Shares of Aurinia Pharmaceuticals saw a handy gain on Friday after the company announced plans for the development of a late-stage trial.
Neothetics saw its stock hit a multiyear high on Wednesday after the firm announced a critical patent approval.
Shares of Paratek Pharmaceuticals saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial.
The road to a pivotal Phase 3 trial usually takes years following an IPO, but Therapix Biosciences may reach that stage in just a few months' time.
Argus likes Integra’s strong growth prospects and its ability to execute on acquisition and mergers that help move the company's needle on growth in revenue and earnings.
Tocagen expects to price more than 7 million shares in the range of $10 to $12 apiece for an initial public offering valued up to about $100 million.
NovoCure saw its shares skyrocket early on Monday after the firm provided an update for its late-stage cancer trial.
Cara Therapeutics has priced more than 4 million shares of common stock at $18 per share in a secondary offering valued up to around $92 million.
Shares of Akari Therapeutics saw a handy gain on Friday after the firm announced that the FDA granted a Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria.
